Insilico, Lila draw nine-figure venture rounds: Finance Report

Insilico and newly launched Lila drew the week’s largest venture rounds, while at least one biotech priced a follow-on that fell short of expectations.

A new $110 million series E round will allow Insilico Medicine Inc. to begin pivotal testing of its inhalable antifibrotic therapy rentosertib (ISM001-055) to treat idiopathic pulmonary fibrosis. The product, Insilico’s most advanced in its pipeline of AI-derived treatments, has led to improvements in forced vital capacity in a Phase IIb study. The biotech has also started clinical testing of TEAD inhibitor ISM6331 to treat mesothelioma and other solid tumors...